JIE MA

Senior Principal Scientist at Adverum Biotechnologies
  • Claim this Profile
Contact Information
us****@****om
(386) 825-5501
Location
Redwood City, California, United States, US
Languages
  • English Native or bilingual proficiency
  • Chinese Native or bilingual proficiency

Topline Score

Topline score feature will be out soon.

Bio

Generated by
Topline AI

You need to have a working account to view this content.
You need to have a working account to view this content.

Credentials

  • Post-doctoral research fellowship at SERI/MEEI/HMS
    Harvard Medical School, Mass Eye and Ear, Schepens Eye Research Institute
    Mar, 2011
    - Nov, 2024

Experience

    • United States
    • Biotechnology Research
    • 1 - 100 Employee
    • Senior Principal Scientist
      • Jan 2023 - Present

  • Adverum Biotechnologies, Inc
    • Redwood City, California, United States
    • Principal Scientist
      • May 2021 - Mar 2023

      – Oversee the design and data-review of pre-clinical studies – Pilot studies testing safety and efficacy of vectors using rodents in house – Regulatory of the cooperations with CROs – Apply gene therapies to treat retinal diseases – Assay development for pre-clinical projects – Quality control – Oversee the design and data-review of pre-clinical studies – Pilot studies testing safety and efficacy of vectors using rodents in house – Regulatory of the cooperations with CROs – Apply gene therapies to treat retinal diseases – Assay development for pre-clinical projects – Quality control

    • United States
    • Biotechnology Research
    • 700 & Above Employee
    • Scientist II
      • Jan 2019 - May 2021

      – Lead the projects of neuro-protection and neuro-regeneration related ophthalmological diseases using gene therapies (viral and non-viral deliveries) and other modalities – Oversee the assay developments to evaluate the efficacy of neuro-protection and neuro-regeneration – In charge of model generation of ocular diseases: ocular hypertension glaucoma model and optic nerve crush, TNF-a induced RGC death model – Neuroprotection by modifying inflammasome pathways – Lead the POC studies using SM, viral and non-viral treatments in ocular diseases – IACUC committee Show less

    • Senior Scientist
      • Jul 2016 - Jan 2019

      Playing a key role in the Retinal Progenitor Program. Working on stem cell (iPS cells and ES cells) culture/maintain and stem cell differentiation for cell therapy. I was in charge of in vivo studies using cell therapies to treat rodent models with inherited ocular diseases including retinal photoreceptor degeneration, retinitis pigmentosa, and generating ocular diseases models including optic nerve degeneration and ocular hypertension. Playing a key role in the Retinal Progenitor Program. Working on stem cell (iPS cells and ES cells) culture/maintain and stem cell differentiation for cell therapy. I was in charge of in vivo studies using cell therapies to treat rodent models with inherited ocular diseases including retinal photoreceptor degeneration, retinitis pigmentosa, and generating ocular diseases models including optic nerve degeneration and ocular hypertension.

    • United States
    • Higher Education
    • 700 & Above Employee
    • Instructor, Junior Faculty
      • Feb 2014 - Jul 2016

      Generated ocular disease rodent models including age-related macular degeneration (AMD), ocular hypertension (glaucoma) and optic nerve degeneration; Intravitreally administrated gene therapy, cell therapy and specific inhibitor/receptor to treat AMD or glaucomatous mice; Estimated solid method to quantify retinal ganglion cells (RGCs) using specific markers; Investigated inflammation enhancing RGC death in gluacomatous mice. As a key investigator, I was in charge of supervising students and technicians in the lab and managing the projects. Show less

    • United States
    • Hospitals and Health Care
    • 700 & Above Employee
    • Investigator, Junior Faculty
      • Feb 2014 - Jul 2016

      Generated ocular disease rodent models including age-related macular degeneration (AMD), ocular hypertension (glaucoma) and optic nerve degeneration; Intravitreally administrated gene therapy, cell therapy and specific inhibitor/receptor to treat AMD or glaucomatous mice; Estimated solid method to quantify retinal ganglion cells (RGCs) using specific markers; Investigated inflammation enhancing RGC death in gluacomatous mice. As a key investigator, I was in charge of supervising students and technicians in the lab and managing the projects. Show less

    • Postdoctoral Fellow
      • Mar 2011 - Jan 2014

      Generated ocular disease rodent models including age-related macular degeneration (AMD), ocular hypertension (glaucoma) and optic nerve degeneration; Intravitreally administrated gene therapy, cell therapy and specific inhibitor/receptor to treat AMD or glaucomatous mice; Estimated solid method to quantify retinal ganglion cells (RGCs) using specific markers; Investigated inflammation enhancing RGC death in gluacomatous mice. As a key investigator, I was in charge of supervising students and technicians in the lab and managing the projects. Show less

    • United States
    • Higher Education
    • 700 & Above Employee
    • Research Associate
      • Aug 2009 - Mar 2011

      Studies of neurophysiology, neuro-morphology and pharmacology.

    • Postdoctoral Fellow
      • Jul 2008 - Jul 2009

      Studies of neurophysiology and animal behavior

    • United States
    • Higher Education
    • 700 & Above Employee
    • Postdoctoral Fellow
      • Mar 2004 - Feb 2007

      Neurophysiology, pharmacology, animal behavior Neurophysiology, pharmacology, animal behavior

Education

  • University of Chinese Academy of Sciences
    Doctor of Philosophy - PhD, Ecology and Behavior
    2001 - 2004
  • Beijing Normal University
    Master’s Degree, Animal Ecology and Physiology
    1998 - 2001
  • Beijing Normal University
    Bachelor’s Degree, Biology
    1994 - 1998

Community

You need to have a working account to view this content. Click here to join now